Peptide Knowledge Base · Cognition
Dihexa: what it is, what the evidence says, and its real status
An angiotensin-IV-derived peptide reported as an extremely potent driver of new synapse formation, essentially no human data.
Short version: a peptide with eye-popping potency claims for building synapses, and almost no human data to anchor them. A caution register, education only.
Can you actually get it?
Plain-English verdict: Education only.
Regulatory status: Research-only · Education only.
Not offered, caution and education only. Dihexa is a research-stage synaptogenic peptide with essentially no human data and unknown long-term safety. It is not FDA-approved and not available.
How does Dihexa work?
An angiotensin-IV analog reported in preclinical work to powerfully promote synapse formation via HGF/c-Met signaling.
What it does — and what it does not do
What it does: Showed strong synaptogenic effects in laboratory models.
What it does not do: It has essentially no human data, is not approved, and is not available, the potency claims are exactly why caution matters.
How honest is the evidence?
Evidence grade D — preclinical; potency claims outrun human data. Read our grading methodology for what each grade means.
What we still don't know: No meaningful human safety or efficacy data; the proliferative mechanism is uncharacterized for risk.
WADA status: Not prohibited.
How it is taken
Not offered; education only.
Who should not take it
Proliferative signaling; no human safety characterization.
Sources
Dihexa / angiotensin-IV synaptogenesis preclinical literature
Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker or the knowledge base.
Last reviewed 2026-08-11 · Peptós.LIFE · Not medical advice.